TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11986264

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) treatment for non-consecutive periods of 2 months and 1 month
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) treatment
Number of subjects: 28
Study: 10569659

Group type: EXPERIMENTAL
Intervention: dl‐sotalol (160 to 320 mg/day)
Number of subjects: 121

Group type: COMPARATOR
Intervention: quinidine sulfate (600 to 800 mg/day)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: dl‐sotalol (for recent-onset AF)
Number of subjects: 121

Group type: COMPARATOR
Intervention: quinidine sulfate (for recent-onset AF)
Number of subjects: 121

Group type: COMPARATOR
Intervention: quinidine sulfate (for chronic AF)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: dl‐sotalol (for chronic AF)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: dl‐sotalol
Number of subjects: 121

Group type: COMPARATOR
Intervention: quinidine sulfate
Number of subjects: 121
Study: 8669516

Group type: EXPERIMENTAL
Intervention: Therapeutic shoes prescribed by clinicians specializing in foot care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 1861917

Group type: EXPERIMENTAL
Intervention: Sulfisoxazole 75 mg/kg per day for 6 months
Number of subjects: 125

Group type: COMPARATOR
Intervention: Bilateral insertion of ventilation tubes (VTs)
Number of subjects: 125
Study: 7103524

Group type: EXPERIMENTAL
Intervention: Etretinate therapy
Number of subjects: 21
Study: 30192324

Group type: EXPERIMENTAL
Intervention: Laparoscopic colonic resection
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 592

Group type: COMPARATOR
Intervention: Open colonic resection
Number of subjects: 592
Study: 26765633

Group type: EXPERIMENTAL
Intervention: 2 g·d of DHA
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 4 g·d of DHA
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 6 g·d of DHA
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: DHA supplementation (irrespective of dose)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 23937408

Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 37
Study: 23772853

Group type: EXPERIMENTAL
Intervention: Perampanel 2-12 mg
Number of subjects: 1109

Group type: COMPARATOR
Intervention: Concomitant EIAEDs (carbamazepine, oxcarbazepine, phenytoin)
Number of subjects: 1109
Study: 20439606

Group type: EXPERIMENTAL
Intervention: Dual-boosted protease inhibitor combinations
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Baseline cleavage site substitutions at positions 128 (p17/p24) and 449 (p1/p6(gag))
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Baseline cleavage site mutation at position 437 (TFP/p6(pol))
Number of subjects: 48
Study: 17069817

Group type: EXPERIMENTAL
Intervention: Educational intervention (workplace 'toolbox')
Number of subjects: 2

Group type: COMPARATOR
Intervention: Reference organisation (no toolbox introduced)
Number of subjects: 2
Study: 16240737

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 12899549

Group type: EXPERIMENTAL
Intervention: Internal fixation with hook‐pins (n=36)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Primary arthroplasty (total or hemiarthroplasty) (n=32)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Primary arthroplasty
Number of subjects: 68
Study: 10596413

Group type: EXPERIMENTAL
Intervention: Multiple dose treatment with surfactant (Curosurf)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Single dose treatment with surfactant (Curosurf)
Number of subjects: 31
Study: 8706486

Group type: EXPERIMENTAL
Intervention: Halothane-based anesthetic
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fentanyl-based anesthetic
Number of subjects: 15

Group type: COMPARATOR
Intervention: Both anesthetic groups pooled
Number of subjects: 15
Study: 1877512

Group type: EXPERIMENTAL
Intervention: Weekly doses of 8.7 mumol (2500 microgram) vitamin A and 46 mumol (20 mg) vitamin E
Number of subjects: 15419

Group type: COMPARATOR
Intervention: 46 mumol vitamin E (control)
Number of subjects: 15419
Study: 6962738

Group type: EXPERIMENTAL
Intervention: Cigarette averaging .64 mg nicotine (P2)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cigarette averaging .38 mg nicotine (P3)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group switched to another brand within ± .1 mg of their usual brand (P2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group switched to another brand within ± .1 mg of their usual brand (P3)
Number of subjects: 22
Study: 31056892

Group type: EXPERIMENTAL
Intervention: MPFF 1000 mg
Number of subjects: 256

Group type: COMPARATOR
Intervention: MPFF 500 mg
Number of subjects: 256
Study: 30400947

Group type: EXPERIMENTAL
Intervention: Rye-based bread (RB + RS2)
Number of subjects: 38

Group type: COMPARATOR
Intervention: White wheat flour bread (WWB)
Number of subjects: 38
Study: 25809810

Group type: EXPERIMENTAL
Intervention: Tailored nutritional guidance for couples with AD
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group meetings with protein-rich snacks
Number of subjects: 40
Study: 24012456

Group type: EXPERIMENTAL
Intervention: < 3 CTC per 7.5 mL blood and KRAS wild-type tumors
Number of subjects: 158

Group type: COMPARATOR
Intervention: ≥ 3 CTCs and KRAS mutated tumors
Number of subjects: 158
Study: 21345850

Group type: EXPERIMENTAL
Intervention: More intense therapy (low-dose hydrochlorothiazide and low-dose felodipine)
Number of subjects: 9711

Group type: COMPARATOR
Intervention: Less-intense therapy (low-dose hydrochlorothiazide and placebo)
Number of subjects: 9711
Study: 19302238

Group type: EXPERIMENTAL
Intervention: Immediate restoration
Number of subjects: 49

Group type: COMPARATOR
Intervention: Delayed restoration
Number of subjects: 49
Study: 17984136

Group type: EXPERIMENTAL
Intervention: Epicardial left atrial cryoablation
Number of subjects: 69

Group type: COMPARATOR
Intervention: Mitral valve surgery alone
Number of subjects: 69
Study: 15042537

Group type: EXPERIMENTAL
Intervention: Resistance training for 12 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (low-protein diet)
Number of subjects: 26
Study: 11682427

Group type: EXPERIMENTAL
Intervention: 12.5% carbohydrate drink (CHO)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo (flavored water)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Overnight fasting
Number of subjects: 252
Study: 10211032

Group type: EXPERIMENTAL
Intervention: Ropivacaine 75 mg in 0.9% saline 60 ml
Number of subjects: 5

Group type: COMPARATOR
Intervention: Bupivacaine 75 mg in 0.9% saline 60 ml and epinephrine 5 micrograms/ml
Number of subjects: 5
Study: 7889580

Group type: EXPERIMENTAL
Intervention: Double-burst stimulation (DBS)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF) stimulation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: DBS
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: TOF
Number of subjects: 44
Study: 2925731

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 140

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 140
Study: 604377

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30987986

Group type: EXPERIMENTAL
Intervention: Exercise intervention (3 days/week for 3 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 25827960

Group type: EXPERIMENTAL
Intervention: 10mg/m(2)/day of oral hydrocortisone in three divided doses
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 24640651

Group type: EXPERIMENTAL
Intervention: Coordination gymnastics combined with magnetic therapy and iodine-bromine baths
Number of subjects: 80
Study: 21570371

Group type: EXPERIMENTAL
Intervention: Hilotherapy mask
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard dressings alone
Number of subjects: 50
Study: 18971509

Group type: EXPERIMENTAL
Intervention: 23-min bout of treadmill walking
Number of subjects: 69

Group type: COMPARATOR
Intervention: Nonexercise period
Number of subjects: 69
Study: 16322489

Group type: EXPERIMENTAL
Intervention: Trials with a treatment window >6 hours
Number of subjects: 32

Group type: COMPARATOR
Intervention: Trials with a treatment window <=6 hours
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Trials conducted in 1 country
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Trials with maximum allowable time from stroke to study enrollment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Exclusion of mild strokes
Number of subjects: 32
Study: 14613518

Group type: EXPERIMENTAL
Intervention: Omacor 1 g, o.d.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo o.d.
Number of subjects: 100
Study: 10942489

Group type: EXPERIMENTAL
Intervention: Vaginal fetal fibronectin measurements
Number of subjects: 13360
Study: 8822290

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE) for 5 days at 30 mg/kg/day in 2 divided doses
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE) for 10 days at 30 mg/kg/day in 2 divided doses
Number of subjects: 719

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (AMX/CL) for 10 days at 40 mg/kg/day in 3 divided doses
Number of subjects: 719
Study: 1464862

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 16

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Deflazacort vs Prednisone
Number of subjects: 16
Study: 6523650

Group type: EXPERIMENTAL
Intervention: Cefuroxime (antibiotic group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no antibiotic)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Overall infection rate
Number of subjects: 65
Study: 31530586

Group type: EXPERIMENTAL
Intervention: Multifactorial context-enhancing functional training program
Number of subjects: 126

Group type: COMPARATOR
Intervention: Functional training
Number of subjects: 126
Study: 29084458

Group type: EXPERIMENTAL
Intervention: Life Skills programme for young adult male offenders
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 96
Study: 26881449

Group type: EXPERIMENTAL
Intervention: Personality-targeted intervention
Number of subjects: 1210
Study: 24567279

Group type: EXPERIMENTAL
Intervention: Omeprazole + lacosamide coadministration
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lacosamide + omeprazole coadministration
Number of subjects: 36

Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lacosamide alone
Number of subjects: 36
Study: 22508376

Group type: EXPERIMENTAL
Intervention: Carbidopa 450 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carbidopa 75 mg/day
Number of subjects: 12
Study: 20224964

Group type: EXPERIMENTAL
Intervention: S‐TOFHLA
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: REALM
Number of subjects: 1796
Study: 17989600

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 21
Study: 15899326

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11943520

Group type: EXPERIMENTAL
Intervention: Hyperventilation group (PaCO2 = 25‐35)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normoventilation group (PaCO2 = 35‐45)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hypoventilation group (PaCO2 = 45‐55)
Number of subjects: 90
Study: 9811379

Group type: EXPERIMENTAL
Intervention: Caffeinated beverages consumed ad lib
Number of subjects: 30

Group type: COMPARATOR
Intervention: Caffeine deprivation (abstained from caffeine)
Number of subjects: 30
Study: 8929932

Group type: EXPERIMENTAL
Intervention: High intensity program (case management plus peer‐supervised housing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium intensity group (peer‐supervised housing only)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Housed control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonhoused control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Program graduates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women in the study
Number of subjects: 0
Study: 2163805

Group type: EXPERIMENTAL
Intervention: BAY m1099 (50 mg thrice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Guar granules (5 g thrice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BAY m1099
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of BAY m1099 and Guar
Number of subjects: 12
Study: 474948

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine 0.4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular morphine 10 mg
Number of subjects: 0
Study: 30382002

Group type: EXPERIMENTAL
Intervention: Probiotics during hospitalization until 8 weeks post-discharge
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Standard care with probiotics
Number of subjects: 388

Group type: COMPARATOR
Intervention: Standard care with placebo
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Negative predictors during inpatient therapeutic care (ITC)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Negative predictors during outpatient therapeutic care (OTC)
Number of subjects: 388
Study: 28931089

Group type: EXPERIMENTAL
Intervention: One-month dietary AGE restriction (LAGE, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuing the same diet (HAGE, n = 10)
Number of subjects: 20
Study: 26138203

Group type: EXPERIMENTAL
Intervention: 100 μg sprifermin
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 23638956

Group type: EXPERIMENTAL
Intervention: Surgical management (curettage)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study: 21854617

Group type: EXPERIMENTAL
Intervention: Grip op Je Dip (GOJD) online group course
Number of subjects: 244

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 244
Study: 19636360

Group type: EXPERIMENTAL
Intervention: Dopamine agonist (levodopa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dopamine antagonist (haloperidol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher anticipated reward
Number of subjects: 0
Study: 17062039

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% foam (CF)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo foam (PF)
Number of subjects: 34
Study: 15105978

Group type: EXPERIMENTAL
Intervention: Multislice CT (CTA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional angiography (DSA)
Number of subjects: 50
Study: 11726616

Group type: EXPERIMENTAL
Intervention: Medium oxygen‐permeable (Dk) RGP lenses
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High oxygen‐permeable (Dk) RGP lenses
Number of subjects: 200

Group type: COMPARATOR
Intervention: Both medium and high oxygen‐permeable (Dk) RGP lenses
Number of subjects: 200
Study: 9141982

Group type: EXPERIMENTAL
Intervention: Nasal steroid (fluticasone) 200 micrograms when needed (up to 400 micrograms/d) + 1-2 tablets of terfenadine daily (max 120 mg/d)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Antihistamine (terfenadine) 1 tablet of 60 mg when needed (max 120 mg/d) + 200-400 micrograms/d of fluticasone nasal spray if needed
Number of subjects: 61
Study: 7968554

Group type: EXPERIMENTAL
Intervention: New context during testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Different context experienced during learning
Number of subjects: 0
Study: 3099611

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium nasal spray for 6 weeks together with terfenadine for 1 week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terfenadine alone for 6 weeks
Number of subjects: 0
Study: 31141465

Group type: EXPERIMENTAL
Intervention: Hatha yoga
Number of subjects: 84

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 84
Study: 30203772

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 28592016

Group type: EXPERIMENTAL
Intervention: Oseltamivir (30‐75 mg, twice daily for 5 days)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control (symptom relief medicines for 5 days)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Oseltamivir (in patients confirmed with positive virus test)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control (in patients confirmed with positive virus test)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Oseltamivir (in patients who completed the course)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control (in patients who completed the course)
Number of subjects: 229
Study: 25903940

Group type: EXPERIMENTAL
Intervention: Suvorexant 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Suvorexant 150 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23916633

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 81
Study: 20835580

Group type: EXPERIMENTAL
Intervention: Air abrasion with 37% phosphoric acid (group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Air abrasion with self-priming etchant (Tyrian-SPE) (group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Turbine with 37% phosphoric acid (group III)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Turbine with self-priming etchant (Tyrian-SPE) (group IV)
Number of subjects: 40
Study: 18182196

Group type: EXPERIMENTAL
Intervention: Infusion pump with 0.5% bupivacaine
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Interscalene regional block
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Interscalene block combined with an infusion pump containing 0.9% saline solution
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Interscalene block combined with an infusion pump containing 0.5% bupivacaine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (Infusion pump with saline solution)
Number of subjects: 76
Study: 15906076

Group type: EXPERIMENTAL
Intervention: Acupuncture at LI 4 and PC 6 points for 15 min (Group A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Acupuncture at LI 4 and PC 6 points for 15 min (Group C)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (Group B) - acupuncture needles inserted subcutaneously
Number of subjects: 29
Study: 12774013

Group type: EXPERIMENTAL
Intervention: 10 mIU IFN‐alpha2b daily for 1 month followed by 3 mIU IFN‐alpha2b 3 times a week with ribavirin
Number of subjects: 35
Study: 10589439

Group type: EXPERIMENTAL
Intervention: Andrographis paniculata dried extract (1200 mg/day)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 8636343

Group type: COMPARATOR
Intervention: Fludrocortisone 0 mg (placebo)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.1 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.2 mg
Number of subjects: 14
Study: 2019178

Group type: COMPARATOR
Intervention: Monosodium glutamate (MSG), 9 g, intravenous loading
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG)
Number of subjects: 6
Study: 6168840

Group type: COMPARATOR
Intervention: Pindolol (10‐45 mg/day)
Number of subjects: 16
Study: 31033396

Group type: EXPERIMENTAL
Intervention: Ad exposure frequency (viewing the ad once, twice, or four times)
Number of subjects: 616
Study: 28324627

Group type: EXPERIMENTAL
Intervention: Buprenorphine induction and dose stabilization during hospitalization followed by post-discharge transition to office-based buprenorphine treatment (OBOT)
Number of subjects: 72
Study: 25872502

Group type: EXPERIMENTAL
Intervention: Mild hypercapnia (PaCO2 50 to 55 mmHg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normocapnia (PaCO2 35 to 45 mmHg)
Number of subjects: 0
Study: 23009254

Group type: EXPERIMENTAL
Intervention: Real-patients PBL (RPBL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Digital PBL (DPBL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Paper PBL (PPBL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lecture-based learning (LBL)
Number of subjects: 120
Study: 21826009

Group type: EXPERIMENTAL
Intervention: HIVIGLOB/sdNVP
Number of subjects: 492

Group type: COMPARATOR
Intervention: sdNVP
Number of subjects: 492
Study: 19180894

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied to one-half of the face, 2-times-per-week for 16 weeks after photodynamic therapy.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vehicle applied to the other half of the face, 2-times-per-week for 16 weeks after photodynamic therapy.
Number of subjects: 25
Study: 17728605

Group type: EXPERIMENTAL
Intervention: Three-phase bone scintigraphy (TPBS) - vascular phase
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Three-phase bone scintigraphy (TPBS) - blood pool phase
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Three-phase bone scintigraphy (TPBS) - delayed phase
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Three-phase bone scintigraphy (TPBS) - any phase positive finding
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no CRPS)
Number of subjects: 26
Study: 13680283

Group type: EXPERIMENTAL
Intervention: 3x2 mg budesonide
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 3x3 mg budesonide
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 3x6 mg budesonide
Number of subjects: 104
Study: 11679989

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2 x 10(6) KIU at induction, continuous infusion of 1 x 10(6) KIU/h, and 1 x 10(6) KIU before reperfusion; n = 10)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Regular-dose aprotinin (2 x 10(6) KIU at induction and continuous infusion of 0.5 x 10(6) KIU/h; n = 8)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 27